Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Outcome Measure:

coughing response

Outcome Description:

Emergence cough was defined as the cough occurrence during peri-extubation period, from sevoflurane discontinuation to 5 min after extubation. The severity of cough was assessed and recorded by the following cough grading system: Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking).

Outcome Time Frame:

from discontinuation of anesthetic agent (sevoflurane) to 5 min after extubation.

Safety Issue:

No

Authority:

South Korea: Institutional Review Board

Study ID:

4-2011-0181

NCT ID:

NCT01617694

Start Date:

June 2011

Completion Date:

November 2011

Related Keywords:

• Thyroid Neoplasm
• dexmedetomidine
• remifentanil
• target-controlled infusion
• Neoplasms
• Thyroid Neoplasms